Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 15/20 | 0.49 |
| ▸ | NMBR | P28336 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL6432975 | 0.96 | SIRT2 (0.47) | SIRT2NMBRALDH1A1NPC1 | |
| SCHEMBL7713289 | 0.95 | SIRT2 (0.46) | SIRT2NMBRALDH1A1NPC1 | |
| Acetic Acid SCHEMBL7659782 | 0.82 | SIRT2 (0.47) | SIRT2NMBRCYP2C19 | |
| SCHEMBL14289994 | 0.81 | SIRT2 (0.46) | SIRT2NMBR | |
| SCHEMBL729745 | 0.81 | SIRT2 (0.44) | SIRT2NMBRKMT2A | |
| SCHEMBL10871413 | 0.80 | SIRT2 (0.41) | SIRT2NMBRALDH1A1 | |
| SCHEMBL10877507 | 0.80 | SIRT2 (0.41) | SIRT2NMBRALDH1A1 | |
| SCHEMBL23278623 | 0.79 | SIRT2 (0.46) | SIRT2NMBR | |
| SCHEMBL6777569 | 0.79 | SIRT2 (0.48) | SIRT2NMBRALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL14901171 | 0.79 | SIRT2 (0.46) | SIRT2NMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114350-A1 | INHIBITORS OF PRENYLTRANSFERASES AS ANTIFUNGAL AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2025-04-10 | — | — | US | disclosed |
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| CN-100404535-C | Organic compounds useful as medicaments for the treatment of aldosterone-mediated conditions | NOVARTIS AG (CH) | 2008-07-23 | — | — | CN | disclosed |
| EP-1537114-B8 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| EP-1537114-B1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| US-6989383-B1 | Method of treating cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-01-24 | — | — | US | disclosed |
| CN-1688583-A | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2005-10-26 | — | — | CN | disclosed |
| US-20050137207-A1 | Method of treating cancer | ROSEN NEAL (US) | 2005-06-23 | — | — | US | disclosed |
| EP-1537114-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-1997036591-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036593-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036587-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997027854-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997027853-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997027752-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997018813-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-05-29 | — | — | WO | disclosed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996037204-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-11-28 | — | — | WO | disclosed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114350-A1 | INHIBITORS OF PRENYLTRANSFERASES AS ANTIFUNGAL AGENTS | FNTA, FNTB, FDPS | SIRT2 440/4885NMBR 4157/4885ALDH1A1 2611/4885 |
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | CYP11B1, CYP27A1, CYP17A1 | SIRT2 4371/4885NMBR 4542/4885ALDH1A1 178/4885 |
| US-20050137207-A1 | Method of treating cancer | FNTA, GGT1, NTPCR | SIRT2 756/4885NMBR 3784/4885ALDH1A1 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.